Powell speech takes center stage in Tuesday’s economic events
SAN FRANCISCO - Telehealth provider Hims & Hers Health, Inc. (NYSE:HIMS) released a white paper revealing that 94% of customers surveyed rated their telehealth experience as equal to or better than traditional in-person care.
The report, titled "Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety," draws from a survey of nearly 2,400 customers and data from routine clinical check-ins across the company’s service categories.
Among key findings, 91% of respondents found the clinical intake process easy to complete, while 83% reported it increased their confidence in starting treatment. Additionally, 83% of customers said they received clear treatment instructions.
The white paper also highlights low rates of reported side effects across treatment categories. Among more than 418,000 weight loss customers using GLP-1 medication, only 0.08% contacted the company about side effects. For mental health services, less than 0.01% of customers sought higher-level care due to side effects, while sexual health and hair loss treatments showed similarly low rates.
"Expanding access to millions of people only matters if the care delivered is grounded in medical excellence, safety, and transparency," said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers, in the press release statement.
The company noted that its Clinical Quality team continuously reviews care outcomes, provider interactions, and medication safety. Affiliated pharmacies follow standards based on FDA, USP, and state pharmacy law requirements for compounded treatments.
Hims & Hers Health operates a health and wellness platform providing telehealth services across multiple treatment categories.
In other recent news, Hims and Hers Health Inc. has been in the spotlight following several developments. The company received a warning letter from the U.S. Food and Drug Administration for making "false or misleading" marketing claims about its compounded semaglutide products. The FDA highlighted issues with statements on the company’s website regarding the similarity of its products to Ozempic and Wegovy. In terms of financial outlook, BofA Securities has reiterated its Underperform rating with a $28.00 price target, noting that September sales growth is projected to be in the low-to-mid 20% range year-over-year, which is below earlier expectations. Meanwhile, Canaccord Genuity maintains a Buy rating with a $68.00 price target, expressing confidence in the company’s long-term growth potential despite recent stock pressure. Additionally, Hims and Hers faced criticism in a New York Times op-ed for its advertising practices, particularly concerning a Super Bowl ad. These developments are part of the ongoing narrative surrounding Hims and Hers as it navigates market and regulatory challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.